Qing Zhang1, Chen Wang2, William A Cliby3. 1. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, USA. 2. Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA. 3. Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: Cliby.william@mayo.edu.
Abstract
OBJECTIVE: Mesenchymal (MES) subtype of high-grade serous ovarian cancer (HGSOC) is associated with worse outcomes including survival and resectability compared with other molecular subtypes. Molecular subtypes have historically been derived from 'tumor', consisting of both cancer and stromal cells. We sought to determine the origins of multiple MES subtype gene signatures in HGSOC. METHODS: Fifteen patients with MES subtype of HGSOC diagnosed between 2010 and 2013 were identified. Formalin-fixed paraffin-embedded (FFPE) blocks from primary surgery were sectioned for immunohistochemistry (IHC) staining of relevant proteins. Eight genes (ACTA2, COL5A1, COL11A1, FAP, POSTN, VCAN, ZEB1 and p-SMAD2) were selected for IHC staining based on their differential expression in MES vs. non-MES subtypes of HGSOC. Slides were scored for intensity and localization and simple statistics were used to compare expression results in cancer vs. stroma and between primary and metastatic sites. RESULTS: COL5A1, VCAN, FAP, and ZEB1 proteins were almost exclusively expressed by stroma as opposed to cancer cells. In addition, stromal expression was dominant for ACTA2, COL11A1, POSTN and p-SMAD2. In general there were minimal differences in expression of proteins between primary and metastatic sites, exceptions being COL5A1 (reduced in metastases) and COL11A1 (increased in metastases). Nuclear p-SMAD2 expression was more common in metastatic stroma. CONCLUSIONS: The existing molecular classification of HGSOC MES subtype reflects a significant stromal contribution, suggesting an important role in HGSOC behavior and thus stroma may be a relevant therapeutic target. Specific patterns of expression indicate that collagens and TGF-β signaling are involved in the metastatic process.
OBJECTIVE: Mesenchymal (MES) subtype of high-grade serous ovarian cancer (HGSOC) is associated with worse outcomes including survival and resectability compared with other molecular subtypes. Molecular subtypes have historically been derived from 'tumor', consisting of both cancer and stromal cells. We sought to determine the origins of multiple MES subtype gene signatures in HGSOC. METHODS: Fifteen patients with MES subtype of HGSOC diagnosed between 2010 and 2013 were identified. Formalin-fixed paraffin-embedded (FFPE) blocks from primary surgery were sectioned for immunohistochemistry (IHC) staining of relevant proteins. Eight genes (ACTA2, COL5A1, COL11A1, FAP, POSTN, VCAN, ZEB1 and p-SMAD2) were selected for IHC staining based on their differential expression in MES vs. non-MES subtypes of HGSOC. Slides were scored for intensity and localization and simple statistics were used to compare expression results in cancer vs. stroma and between primary and metastatic sites. RESULTS:COL5A1, VCAN, FAP, and ZEB1 proteins were almost exclusively expressed by stroma as opposed to cancer cells. In addition, stromal expression was dominant for ACTA2, COL11A1, POSTN and p-SMAD2. In general there were minimal differences in expression of proteins between primary and metastatic sites, exceptions being COL5A1 (reduced in metastases) and COL11A1 (increased in metastases). Nuclear p-SMAD2 expression was more common in metastatic stroma. CONCLUSIONS: The existing molecular classification of HGSOC MES subtype reflects a significant stromal contribution, suggesting an important role in HGSOC behavior and thus stroma may be a relevant therapeutic target. Specific patterns of expression indicate that collagens and TGF-β signaling are involved in the metastatic process.
Authors: Tsz-Lun Yeung; Cecilia S Leung; Kwong-Kwok Wong; Goli Samimi; Melissa S Thompson; Jinsong Liu; Tarrik M Zaid; Sue Ghosh; Michael J Birrer; Samuel C Mok Journal: Cancer Res Date: 2013-07-03 Impact factor: 12.701
Authors: Alexandre Calon; Elisa Espinet; Sergio Palomo-Ponce; Daniele V F Tauriello; Mar Iglesias; María Virtudes Céspedes; Marta Sevillano; Cristina Nadal; Peter Jung; Xiang H-F Zhang; Daniel Byrom; Antoni Riera; David Rossell; Ramón Mangues; Joan Massagué; Elena Sancho; Eduard Batlle Journal: Cancer Cell Date: 2012-11-13 Impact factor: 31.743
Authors: Richard W Tothill; Anna V Tinker; Joshy George; Robert Brown; Stephen B Fox; Stephen Lade; Daryl S Johnson; Melanie K Trivett; Dariush Etemadmoghadam; Bianca Locandro; Nadia Traficante; Sian Fereday; Jillian A Hung; Yoke-Eng Chiew; Izhak Haviv; Dorota Gertig; Anna DeFazio; David D L Bowtell Journal: Clin Cancer Res Date: 2008-08-15 Impact factor: 12.531
Authors: Upasana Ray; Deok-Beom Jung; Ling Jin; Yinan Xiao; Subramanyam Dasari; Sayantani Sarkar Bhattacharya; Prabhu Thirusangu; Julie K Staub; Debarshi Roy; Bhaskar Roy; S John Weroha; Xiaonan Hou; James W Purcell; Jamie N Bakkum-Gamez; Scott H Kaufmann; Nagarajan Kannan; Anirban K Mitra; Viji Shridhar Journal: Cancer Res Date: 2022-03-15 Impact factor: 13.312
Authors: Andrea Mariani; Chen Wang; Ann L Oberg; Shaun M Riska; Michelle Torres; Joseph Kumka; Francesco Multinu; Gunisha Sagar; Debarshi Roy; Deok-Beom Jung; Qing Zhang; Tommaso Grassi; Daniel W Visscher; Vatsal P Patel; Ling Jin; Julie K Staub; William A Cliby; Saravut J Weroha; Kimberly R Kalli; Lynn C Hartmann; Scott H Kaufmann; Ellen L Goode; Viji Shridhar Journal: Gynecol Oncol Date: 2019-06-14 Impact factor: 5.482
Authors: Matthew Schwede; Levi Waldron; Samuel C Mok; Wei Wei; Azfar Basunia; Melissa A Merritt; Constantine S Mitsiades; Giovanni Parmigiani; David P Harrington; John Quackenbush; Michael J Birrer; Aedín C Culhane Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-12-23 Impact factor: 4.254
Authors: Michael Wessolly; Elena Mairinger; Sabrina Borchert; Agnes Bankfalvi; Pawel Mach; Kurt Werner Schmid; Rainer Kimmig; Paul Buderath; Fabian Dominik Mairinger Journal: Front Oncol Date: 2022-03-03 Impact factor: 6.244
Authors: Ludwig Geistlinger; Sehyun Oh; Marcel Ramos; Lucas Schiffer; Rebecca S LaRue; Christine M Henzler; Sarah A Munro; Claire Daughters; Andrew C Nelson; Boris J Winterhoff; Zenas Chang; Shobhana Talukdar; Mihir Shetty; Sally A Mullany; Martin Morgan; Giovanni Parmigiani; Michael J Birrer; Li-Xuan Qin; Markus Riester; Timothy K Starr; Levi Waldron Journal: Cancer Res Date: 2020-08-03 Impact factor: 12.701
Authors: Allison L Hunt; Nicholas W Bateman; Waleed Barakat; Sasha Makohon-Moore; Brian L Hood; Kelly A Conrads; Ming Zhou; Valerie Calvert; Mariaelena Pierobon; Jeremy Loffredo; Tracy J Litzi; Julie Oliver; Dave Mitchell; Glenn Gist; Christine Rojas; Brian Blanton; Emma L Robinson; Kunle Odunsi; Anil K Sood; Yovanni Casablanca; Kathleen M Darcy; Craig D Shriver; Emanuel F Petricoin; Uma N M Rao; G Larry Maxwell; Thomas P Conrads Journal: iScience Date: 2021-06-21
Authors: Ye Hu; Barbie Taylor-Harding; Yael Raz; Marcela Haro; Maria Sol Recouvreux; Enes Taylan; Jenny Lester; Joshua Millstein; Ann E Walts; Beth Y Karlan; Sandra Orsulic Journal: Front Cell Dev Biol Date: 2020-07-17
Authors: Siel Olbrecht; Pieter Busschaert; Junbin Qian; Adriaan Vanderstichele; Liselore Loverix; Toon Van Gorp; Els Van Nieuwenhuysen; Sileny Han; Annick Van den Broeck; An Coosemans; Anne-Sophie Van Rompuy; Diether Lambrechts; Ignace Vergote Journal: Genome Med Date: 2021-07-09 Impact factor: 11.117